0001104659-26-038859
SEC filingCytoSorbents Corporation received a 180-day extension from Nasdaq until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing.
CytoSorbents Corporation faces ongoing Nasdaq listing challenges due to failure to maintain a $1.00 minimum bid price for its Common Stock, par value $0.001 per share. The company initially fell out of compliance on October 2, 2025, after 30 consecutive business days below the threshold, triggering a first 180-day extension to March 31, 2026, under Nasdaq Listing Rule 5810(c)(3)(A). On April 1, 2026, it secured a second 180-day extension to September 28, 2026, providing additional time to achieve 10 consecutive trading days at or above $1.00 per share. This extension maintains the stock's current Nasdaq listing status without altering SEC reporting duties, offering temporary relief. The company is actively monitoring its bid price and evaluating strategies, including a potential reverse stock split, though success is uncertain. Failure to comply by the deadline risks delisting proceedings, which could impair liquidity, investor confidence, and access to capital markets for this Delaware corporation.